Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8103942 | 1.00 | CES2 (0.46) | CES2LMNATSHRNAAAALDH1A1 | |
| SCHEMBL133243 | 0.92 | ALDH1A1 (0.50) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL3389849 | 0.92 | TSHR (0.44) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL3393592 | 0.92 | TSHR (0.44) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL3393797 | 0.92 | TSHR (0.44) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL3389814 | 0.92 | TSHR (0.44) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL3391088 | 0.92 | TSHR (0.44) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL3391092 | 0.92 | TSHR (0.44) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL28961008 | 0.90 | ALDH1A1 (0.48) | CES2LMNATSHRALDH1A1PRKCA | |
| SCHEMBL3390286 | 0.90 | TSHR (0.46) | CES2LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288186-B1 | Preparation process of vinyl ether compounds | DAICEL CHEM (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-7271297-B2 | Process for producing vinyl ether compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1826196-A2 | Vinyl ether compounds | Daicel Chemical Industries, Ltd. (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-20060205957-A1 | Process for producing vinyl ether compounds | ISHII YASUTAKA | 2006-09-14 | — | — | US | disclosed |
| US-7074970-B2 | Process for producing vinyl ether compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20030083529-A1 | Process for producing vinyl ether compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1288186-A2 | Vinyl ether compounds and preparation process thereof | Daicel Chemical Industries, Ltd. (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205957-A1 | Process for producing vinyl ether compounds | ETV6, CYP3A4, SUV39H2 | CES2 835/4885LMNA 3862/4885TSHR 1315/4885 |
| US-20030083529-A1 | Process for producing vinyl ether compounds | SRD5A2, RPS4X, RUVBL2 | CES2 773/4885LMNA 3433/4885TSHR 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.